We report, to our knowledge, the first case of Müllerian adenosarcoma arising in the urinary bladder with extensive clinicopathologic, immunohistochemical, and molecular analyses. Because of the tendency of lowgrade Müllerian adenosarcomas to recur and/or develop stromal overgrowth, discerning this diagnostic entity from benign extrauterine processes (such as endometriosis) has important diagnostic and clinical implications. Background: Müllerian adenosarcoma is a biphasic neoplasm most commonly occurring in the uterus and less frequently of the ovary. It has been rarely described to occur in other sites such as peritoneum and liver. Patients and Methods: In this study, we report the clinicopathologic, immunohistochemical and molecular features of a primary Müllerian adenosarcoma of the urinary bladder in a 62-year-old woman. To our knowledge, this is the first report of detailed pathologic characterization of Müllerian adenosarcoma primary to the urinary bladder in the literature. Results: Light microscopy showed a biphasic epithelial and stromal tumor with benign-appearing glands surrounded by densely cellular endometrial-type stroma that is densely cellular with increased mitotic figures. The stroma surrounding the glands was more cellular than the intervening areas, which were more loose and edematous. Immunohistochemistry staining revealed positive staining for Pax-2/8 within the glands, for positive CD10 and WT-1 within the spindle cell stroma, and for estrogen and progesterone receptors in both. Staining for desmin, GATA3, p63, and human papillomavirus was negative. Molecular analyses identified mutations in protein kinase B E17K, fms related tyrosine kinase 3 D835N, KRAS proto-oncogene, GTPase G12D, and HRAS proto-oncogene, GTPase G12S. These novel molecular aberrations have yet to be reported in the medical literature. X chromosome inactivation analysis revealed a clonal pattern in the stromal component and a nonclonal pattern in the epithelial component. Currently, the patient is disease/recurrence-free after regular follow-up of approximately 84 months. Conclusion: This case represents, to our knowledge, the first reported diagnosis of Müllerian adenosarcoma arising in the urinary bladder with extensive clinicopathologic, immunohistochemical, and molecular analyses.
Introduction
Müllerian (mesodermal) adenosarcoma is a distinctive type of mixed epithelial and mesenchymal tumor of the female genital tract that was first described in 1974. 1 These tumors are most often found in the uterus [1] [2] [3] ovary is the most common extrauterine site. 4 These tumors have also been found in the pelvis, [5] [6] [7] vagina, 8 and liver. 9 The epithelial component is typically composed of benign-most often endometrioid, but can also be mucinous (endocervical), ciliated, squamous, or serous. 2 Occasionally, tumors with an atypical glandular component have been described. 2 The mesenchymal component usually consists of a low-grade malignant stroma which may exhibit overgrowth, sometimes significant, compared with the epithelial component. Tumors with sarcomatous overgrowth and aggressive clinical course have been described. 1 There are 13 reported cases of Müllerian adenosarcoma that occurred in patients being treated with tamoxifen therapy. [10] [11] [12] [13] [14] [15] We report a case of Müllerian adenosarcoma of the urinary bladder that occurred in a patient with a long-standing history of endometriosis. In addition to an extensive immunohistochemical panel, we performed next-generation sequencing (NGS), virtual karyotype analysis, and X chromosome inactivation analysis. To our knowledge, this is the first case of Müllerian adenosarcoma primary to the urinary bladder with concurrent histopathologic, immunohistochemical, and molecular analyses, including novel molecular aberrations yet to be reported in the literature.
Patients and Methods

Clinical Presentation
A 62-year-old woman presented for urological evaluation because of gross hematuria. Her surgical history included a hysterectomy at an outside institution 15 years previously. Pathologic findings in the uterus from that procedure were not known. Cystoscopy had been performed 12 years previously for hematuria, which showed a mass at the base of the urinary bladder clinically described as an endometrioma. This was reported to be compatible with a known history of endometriosis in conjunction with a urinary tract infection at that time. Pathology from this previous resection was not available for review.
Due to recurrent hematuria, cystoscopy and subsequent transurethral resection of a 2-to 3-cm bladder mass located adjacent to the right ureteral orifice was performed, clinically believed to represent a recurrent endometrioma. Pathologic review of the specimen yielded a diagnosis of endometrial-type tissue with atypical spindle cell proliferation. Because of the suspicion for a lowgrade Müllerian adenosarcoma and the inability to completely resect the lesion transurethrally, a partial cystectomy was performed. Intraoperatively, the lesion appeared to extend into the bladder wall and the right distal ureter.
Pathologic evaluation of the submitted specimens identified a urinary bladder-based tumor consisting of benign endometrial glands surrounded by highly cellular and atypical spindle cells consistent with a Müllerian (mesodermal) adenosarcoma. Background endometriosis was also identified. Surgical margins were negative and the lesion was considered completely excised. Lymph nodes were not sampled.
Since the repair, the patient has had no additional complications from the procedure and is disease-free to date after close observation and regularly scheduled follow-up (approximately 84 months).
Immunohistochemistry and Molecular Analyses
A search through our institution's surgical pathology files identified the previous transurethral resection of the urinary bladder and subsequent partial cystectomy. Hematoxylin and eosin as well as immunohistochemical stains (with appropriate controls) from both specimens were reviewed. Paraffin blocks were obtained for molecular studies. This review was approved by Indiana University institutional review board. Molecular studies including NGS, single nucleotide polymorphism array assay, and X chromosome inactivation analysis were performed.
DNA was obtained from selected formal fixed paraffin embedded (FFPE) tissue blocks to obtain nuclei acid extract to perform multiplexed targeted sequencing assays to detect for mutations. Regions of viable tumor were selected by an experienced genitourinary pathologist (L.C.) on hematoxylin and eosin-stained slides and corresponding unstained slides were deparaffinized with 2 washes of xylene, 15 minutes each, and subsequently washed twice with absolute ethanol, 10 minutes each, and then air-dried in a fume hood. Subsequent protein digestion and DNA extraction were completed. Prescreening for specimen adequacy was performed according to the protocols of TruSeq Amplicon Cancer Panel quality control kit for FFPE samples (Illumina, San Diego, CA). When the sample was deemed adequate, the extracted DNA was analyzed via single-tube reaction evaluating 48 different genes targeted by 212 amplicons using the Illumina MiSeq system. For virtual karyotyping, DNA was obtained from manually microdissected 10-mm paraffin sections according to a previously described protocol and processed with an FFPE-optimized protocol on the basis of the GeneChip Mapping 250K Nsp SNP (single nucleotide polymorphism) Assay Kits (Affymetrix, Santa Clara, CA) as previously described. [16] [17] [18] X chromosome inactivation analysis was performed using DNA prepared from the cystectomy specimen, using methods previously described. [19] [20] [21] In the analysis we used a highly polymorphic CAG repeat in exon 1 of the human androgen receptor (AR) gene on chromosome Xp11-12. Briefly, the DNA extract was digested with HhaI (New England Biolabs Inc, Beverly, MA) and amplified in a polymerase chain reaction mixture containing 0.1 mL of a a- Müllerian Adenosarcoma of the Urinary Bladder using 6.5% denaturing polyacrylamide gel at 80 W for 3 hours, followed by autoradiography with Biomax MS film (Kodak Company, Rochester, NY) for 8 to 18 hours. Control tissue yielded an appropriate reaction.
Results
Histopathologic Findings
The partial cystectomy specimen consisted of part of the urinary bladder, anterior vaginal wall, and right ureteral orifice measuring 6.0 Â 5.0 Â 3.6 cm. A distinct mass was not appreciated; however, sectioning revealed a gray-white to red-brown cut surface remarkable for fibrosis admixed with areas of softening. These foci connected with lobulated and polypoid areas located on the mucosal surface.
The tumor was centered in the muscular wall of the urinary bladder, involving the adjacent perivesical and periureter soft tissue. The tumor was characterized by benign-appearing glands lined by predominantly cuboidal cells with variably eosinophilic cytoplasm. Mitotic figures and nuclear atypia were essentially absent ( Figure 1A and B). Occasionally, glands were lined by flattened and pseudostratified epithelium. The glands were surrounded by endometrialtype stroma that was densely cellular with mild nuclear atypia and increased mitoses (up to 3 per 10 high-powered fields; Figure 1C and D). The stroma surrounding the glands were more cellular than the intervening areas which was looser, edematous, and somewhat myoid-appearing ( Figure 1E ). The tumor also included intraglandular papillary-like projections (lined by bland cuboidal and occasionally pseudostratified cells) resembling phyllodes tumor of the breast ( Figure 1F) . Compared with the previous transurethral resection, the stroma in the partial cystectomy specimen was more atypical in appearance and indeed possessed features of low-grade malignancy. There was also intravascular tumor in thin-and thick-walled vessels (Figure 2A ). Heterologous stromal elements and high-grade sarcomatous overgrowth were not identified. The uninvolved urinary bladder contained foci of endometriosis. The tumor focally extended to cauterized muscularis propria in the main specimen, but it was unknown whether this area represented true margin. All additional inked and separately submitted margins were negative for tumor.
Immunohistochemical Findings
The benign glandular elements labeled immunohistochemically for Pax-2, Pax-8, and CK7 (focal, patchy; Figure 3A and B). Staining within the sarcomatous stroma yielded positive immunoreactivity for CD10, WT-1, and smooth muscle actin (patchy; Figure 3C -E). CA-125, ER, PR, and b-catenin (nuclear) were positive in both components ( Figure 3F-H) . Staining for CK20, desmin, GATA3, HPV, p63, and TTF-1 was negative in both components. Staining for ERG and elastin highlighted tumor within lymphovascular spaces ( Figure 2B ). Ki-67 demonstrated a proliferation index of approximately 1%.
Mutation Analysis
Multiplexed targeted sequencing (NGS) identified the following mutations: HRAS proto-oncogene, GTPase (HRAS) G12S, KRAS proto-oncogene, GTPase (KRAS) G12D, protein kinase B (AKT1) E17K, and fms related tyrosine kinase 3 (FLT3) D835N. 
X Chromosome Inactivation Analysis
Discussion
Primary Müllerian (mesodermal) adenosarcoma of the urinary bladder is an exceptionally rare tumor with no previous report of extensive immunohistochemical or molecular findings in the literature. In this article, we report, to our knowledge, the first case of Müllerian adenosarcoma of the urinary bladder with extensive morphologic and immunophenotypic classification in addition to detection of novel molecular aberrations including AKT1, HRAS, FLT3, and KRAS somatic mutations using NGS, imbalances of chromosomes 1 and 3, as well as X chromosome inactivation.
Previous extragynecologic tract cases of Müllerian adenosarcoma have been reported in the peritoneum, ureter, liver, prostate, testis, and seminal vesicles. [22] [23] [24] [25] Although the etiologies of these rare occurrences of Müllerian adenosarcoma in men have yielded several hypotheses of their origin, the extrauterine/ovarian cases within the female population have been almost exclusively associated with endometriosis (or Müllerianosis). 22 Additionally, the association between mesodermal adenosarcoma and tamoxifen therapy is well documented; however, our patient had no reported use of tamoxifen. [10] [11] [12] [13] [14] [15] Histopathologically, Müllerian/mesodermal adenosarcoma is a biphasic neoplasm consisting of malignant mesenchymal and benign (to mildly atypical) epithelial components. 1 The epithelial component typically consists of evenly distributed glands lined by endometrioidlike epithelium (cuboidal or columnar cells with occasional pseudostratification) that is not overtly malignant. The background mesenchymal stroma is variably cellular, with increased cellularity around the benign glands creating a "cuffed or collared" appearance. 4 The stromal cells are mild to moderately atypical with a variable To our knowledge, this is only the third proposed case of Müllerian adenosarcoma of the urinary bladder published in peerreviewed journals. 27, 28 The first reported case had a very limited description of morphologic features and was postulated to arise out of endometriosis in the prevesical fat rather than the urinary bladder. 27 Additionally, immunohistochemical or molecular studies were not performed. 27 The second previously reported occurrence was a single case of presumed urinary bladder adenosarcoma in 2002, although the pathology was never specifically reviewed to confirm the diagnosis. 28 Limited immunohistochemical findings were described (per report, without review) and no molecular studies were performed. Findings in our case are diagnostic of Müllerian adenosarcoma according to morphologic, immunophenotypic, and molecular findings. The stromal features including increased mitotic activity, cellular atypia, and "cuffing" around benign glands exceed any benign process. Additionally, the phyllodes-like growth patterns in conjunction with our immunophenotypic findings are quite consistent with this diagnosis. With no stromal overgrowth identified, a classification of low-grade adenosarcoma was most appropriate. Few studies have evaluated molecular aberrations seen in primary uterine Müllerian adenosarcoma. Cytogenetic and molecular analyses 29, 30 Additionally, somatic mutations of numerous genes including MDM2 proto-oncogene, cyclin-dependent kinase 4, DNA damage inducible transcript 3, cyclin-dependent kinase inhibitor 2A, fibroblast growth factor receptor 2 as well as alterations in the phsophatidlyinositol-4,5-bisphospate 3-kinase catalytic subunit alpha/AKT/phosphotase and tensin homolog pathway have been identified. [30] [31] [32] One previous study evaluated tumors using DNA flow cytometric analysis and while assessing for DNA ploidy, of which a subset were DNA diploid and all cases had an S-phase fraction < 10%. 33 After an extensive literature search, we have found a significant paucity of molecular/cytogenetic studies of extrauterine mesodermal adenosarcomas. Although our findings in the AKT1 pathway are similar to those previously reported in primary uterine adenosarcoma, the mutations of HRAS, KRAS, and FLT3 are unique. It should be noted that the TruSeq Amplicon-Cancer Panel (Illumina) used to analyze this tumor (using NGS) did evaluate for various other previously described mutations and these were not identified in this tumor. Our reporting of chromosomal imbalances in chromosome 1 and 3 are the first of their kind in Müllerian adenosarcoma. Of note, the 3p loss region did not include the Von Hippel-Lindau tumor suppressor gene, but it did include the polybromo 1 (PBRM1) gene. Although PBRM1 has been reported to be mutated in a high percentage of clear-cell renal cell carcinoma tumors, we found no previous report of this gene being lost or mutated in Müllerian adenosarcomas. 34 The differential diagnosis in a case such as this depends on the presumed site of origin for the lesion. Because of the localization of the tumor to the urinary bladder wall, primary bladder neoplasia, neoplasia arising out of metaplasia, or a metastatic lesion from another primary site should be primary considerations. Primary sarcomatous lesions of the urinary bladder relevant to the differential diagnosis would include leiomyosarcoma and sarcomatoid urothelial carcinoma. Although leiomyosarcoma is the most common bladder sarcoma, this tumor lacked morphologic features typically associated with leiomyosarcoma including interlacing fascicles of cells with cigar-shaped nuclei and lacked significant immunoreactivity with desmin, caldesmon, or smooth muscle actin. 35 A diagnosis of sarcomatoid urothelial carcinoma could be considered; however, the lack of a malignant epithelial component, presence of benign glandular morphology, and lack of immunoreactivity with p63, GATA3, or cytokeratin (within the sarcomatous component) argued against this diagnosis.
36
Previously reported mass-forming lesions of the urinary bladder associated with endometriosis, or less commonly Müllerian osis, include mass-forming endometriosis, clear-cell adenocarcinoma, endometrioid adenocarcinoma, and endometrial stroma sarcoma. [37] [38] [39] Because of the stromal cellularity, infiltrative nature, increased mitotic activity, and nuclear atypia, features in the stromal component of this lesion far surpassed what is expected in a benign endometrioma. 40 Although clear-cell or endometrioid adenocarcinoma arising out of endometriosis could create a mass-forming lesion with glandular morphology, these diagnoses were not a consideration in this case because the lesion lacked a malignant epithelial component. Because of the stromal predominance of these lesions, low-grade endometrial stromal sarcoma (ESS) could also be a diagnostic consideration. Tian et al previously described a case series of 6 ESSs involving the urinary bladder. 39 Although the immunophenotypic overlap is intriguing, their study only described a single case arising out of the urinary bladder which exhibited similar immunophenotypic characteristics but lacked the benign epithelial component. 39 Adenosarcomas have been described to recur in up to 30% of cases; however, metastasis is very uncommon and has only been reported in cases of stromal overgrowth. [41] [42] [43] Although the pathology from this patient's remote hysterectomy was unknown at the time of her current diagnosis, it is highly unlikely this represents a metastasis from a previous uterine, ovarian, or cervical adenosarcoma. Given the location being centered in the urinary bladder wall with lack of involvement of the vaginal wall, this tumor does not represent a vaginal primary extending into the urinary bladder. Of note, the patient's previous resection of a clinically assessed endometrioma very well could have been an undiagnosed Müllerian adenosarcoma, which subsequently recurred. Unfortunately, the absence of previous pathology material makes this purely speculative. Findings in our case are diagnostic of Müllerian adenosarcoma by morphologic and immunophenotypic findings. The stromal features including increased mitotic activity, cellular atypia, and "cuffing" around benign glands exceed that of a benign process. Additionally, the phyllodes-like growth patterns in conjunction with our immunophenotypic findings are quite consistent with this diagnosis. With no stromal overgrowth identified, a classification of low-grade adenosarcoma was most appropriate.
Conclusion
Overall, extrauterine Müllerian adenosarcoma of the urinary bladder is exceedingly rare. We feel that this represents the first study of extragynecologic Müllerian (mesodermal) adenosarcoma that includes extensive immunophenotypic studies and molecular analysis with novel cytogenetic findings including mutations in KRAS, HRAS, AKT1, and FLT3. The possibility for endometriosis to form mass-like lesions in the urinary bladder is well known. Because of the tendency of low-grade Müllerian adenosarcomas to recur and/or develop stromal overgrowth, discerning this diagnostic entity from benign extrauterine processes (such as endometriosis) has important diagnostic and clinical implications.
Clinical Practice Points
Extrauterine Müllerian adenosarcoma is rare. We report the clinicopathologic, immunohistochemical, and molecular features of a primary Müllerian adenosarcoma of the bladder. The immunohistochemistry profile included positive staining for Pax8 within the glands, and for CD10 and WT-1 within the spindled stroma. Molecular analyses identified mutations in AKT1 E17K, FLT3 D835N, KRAS G12D, and HRAS G12S. X chromosome inactivation analysis revealed a clonal pattern in the stromal component and a nonclonal pattern in the epithelial component. Because of the tendency of low-grade Müllerian adenosarcomas to recur and/or develop stromal overgrowth, discerning this diagnostic entity from benign extrauterine processes (such as endometriosis) has important diagnostic and clinical implications.
